Department of Anaesthesiology, Aarhus University Hospital, Denmark.
Department of Mathematics, University of Innsbruck, Innsbruck, Austria.
Thromb Haemost. 2020 Mar;120(3):392-399. doi: 10.1055/s-0039-3402762. Epub 2020 Jan 23.
Craniosynostosis surgery in small children is very often associated with a high blood loss. Tranexamic acid (TXA) reduces blood loss during this procedure, although the potential underlying coagulopathy in these children is not known in detail. Objective was to determine the nature of any coagulopathy found during and after craniosynostosis surgery and to characterize the effect of TXA on fibrin clot formation, clot strength, and fibrinolysis.
Thirty children received either TXA (bolus dose of 10 mg/kg followed by 8 hours continuous infusion of 3 mg/kg/h) or placebo. Dynamic whole blood clot formation assessed by thromboelastometry, platelet count, dynamic thrombin generation/thrombin-antithrombin, clot lysis assay, and fibrinogen/factor XIII (FXIII) levels were measured. Additionally, clot structure was investigated by real-time live confocal microscopy and topical data analysis.
Increased ability of thrombin generation was observed together with a tendency toward shortened activated partial thromboplastin time and clotting time. Postoperative maximum clot firmness was higher among children receiving TXA. FXIII decreased significantly during surgery in both groups.Resistance toward tissue plasminogen activator-induced fibrinolysis was higher in children that received TXA, as evidenced by topical data analysis and by a significant longer lysis time. Fibrinogen levels were higher in the TXA group at 24 hours.
A significant coagulopathy mainly characterized by changes in clot stability and not parameters of thrombin generation was reported. Tranexamic acid improved clot strength and reduced fibrinolysis, thereby avoiding reduction in fibrinogen levels.
小儿颅缝早闭手术常伴有大量失血。氨甲环酸(TXA)可减少手术过程中的出血量,但目前尚不清楚这些儿童潜在的凝血功能障碍的详细情况。目的是确定在颅缝早闭手术期间和之后发现的任何凝血功能障碍的性质,并描述 TXA 对纤维蛋白凝块形成、凝块强度和纤维蛋白溶解的影响。
30 名儿童接受 TXA(首剂 10mg/kg,随后 8 小时持续输注 3mg/kg/h)或安慰剂治疗。通过血栓弹性描记术评估全血动态凝块形成、血小板计数、动态凝血酶生成/凝血酶抗凝血酶、凝块溶解测定以及纤维蛋白原/因子 XIII(FXIII)水平。此外,通过实时实时共聚焦显微镜和局部数据分析来研究凝块结构。
观察到凝血酶生成能力增加,同时活化部分凝血活酶时间和凝血时间缩短的趋势。接受 TXA 治疗的儿童术后最大凝块硬度较高。两组术后 FXIII 均显著下降。接受 TXA 治疗的儿童对组织型纤溶酶原激活物诱导的纤维蛋白溶解的抵抗性更高,这一点可以通过局部数据分析和明显更长的溶解时间来证明。TXA 组 24 小时时纤维蛋白原水平升高。
报告了一种主要表现为凝块稳定性变化而非凝血酶生成参数变化的明显凝血功能障碍。氨甲环酸可改善凝块强度并减少纤维蛋白溶解,从而避免纤维蛋白原水平降低。